Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are currently receiving, or are planning to receive, a type of cancer medication called a BTK inhibitor or venetoclax
- People who are 18 years of age or older, of any gender
- People who are willing to follow all study procedures and are available for the full duration of the study
- People who are able to understand the study and are willing to sign a written consent form
Who may not be able to join:
- People who have had a serious heart condition in the past 3 months, such as a heart attack or severely worsening heart failure
- People who are currently pregnant or breastfeeding, as BTK inhibitor medications are not considered safe for use during pregnancy or nursing
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christine E Gruessner, M.D., National Heart, Lung, and Blood Institute (NHLBI)
Phone: (301) 402-0797
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
arrhythmogenic cardiac effects of BTKi and sudden death within the first 12 months of BTKi therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.